Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.

BMC cancer - 18 Oct 2013

Heublein Sabine, Grasse Katinka, Hessel Harald, Burges Alexander, Lenhard Miriam, Engel Jutta, Kirchner Thomas, Jeschke Udo, Mayr Doris

Abstract excerpt

BACKGROUND: Patients diagnosed for a serous ovarian borderline tumor (s-BOT) typically present with an excellent clinical outcome. However there have been controversies concerning the prognostic impact of so-called implants, an extra ovarian spread occurring alongside the s-BOT in certain cases. It remains obscure whether these implants actually resemble metastasis owning the same genetic pattern as the ovarian...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase Inhibitor p16
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Heterogeneity

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24139521
DOI: 10.1186/1471-2407-13-483
PMCID: PMC4015926

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.PMID 24139521Read ↗

Molecular Landscape of Borderline Ovarian Tumors: A Systematic ReviewSemantic proximity Read ↗

Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants.Semantic proximity Read ↗

Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.Semantic proximity Read ↗

Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.Semantic proximity Read ↗

KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.Semantic proximity Read ↗

Peritoneal Serous Borderline Tumour with Ultra-Mutated NGS Profile Including POLE E, BRAF, RB1, HER2 and P53 Mutations : A Case Report.Semantic proximity Read ↗

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.Semantic proximity Read ↗

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.Semantic proximity Read ↗

Serous borderline tumours of the ovary.Semantic proximity Read ↗

The molecular pathology of ovarian serous borderline tumors.Semantic proximity Read ↗

Histopathologic features of ovarian borderline tumors are not predictive of clinical outcome.Semantic proximity Read ↗

v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.